Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study)

Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study)

Abstract Objective Our study assessed perampanel monotherapy in patients (aged ≥12 years) with focal‐onset seizures (FOS) with or without focal to bilateral tonic‐clonic seizures (FBTCS) in Japan and South Korea. Methods Study 342 (NCT03201900; FREEDOM) is a single‐arm, open‐label, Phase III study....

Full description

Bibliographic Details
Main Authors: Takamichi Yamamoto, Sung Chul Lim, Hirotomo Ninomiya, Yuichi Kubota, Won Chul Shin, Dong Wook Kim, Dong Jin Shin, Tohru Hoshida, Koji Iida, Taku Ochiai, Risa Matsunaga, Hiroyuki Higashiyama, Hidetaka Hiramatsu, Ji Hyun Kim
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Epilepsia Open
Subjects:
antiepileptic drug
focal‐onset seizures
monotherapy
perampanel
seizure freedom
Online Access:https://doi.org/10.1002/epi4.12398

Internet

https://doi.org/10.1002/epi4.12398

Similar Items